SALVADORI, Severo
 Distribuzione geografica
Continente #
NA - Nord America 26.393
AS - Asia 11.660
EU - Europa 6.383
SA - Sud America 1.697
Continente sconosciuto - Info sul continente non disponibili 273
AF - Africa 242
OC - Oceania 22
Totale 46.670
Nazione #
US - Stati Uniti d'America 25.854
SG - Singapore 4.282
CN - Cina 3.108
UA - Ucraina 1.316
BR - Brasile 1.306
DE - Germania 1.298
VN - Vietnam 1.133
HK - Hong Kong 1.041
TR - Turchia 884
IT - Italia 854
GB - Regno Unito 821
FI - Finlandia 517
FR - Francia 409
SE - Svezia 391
CA - Canada 286
RU - Federazione Russa 281
JP - Giappone 225
BD - Bangladesh 218
IN - India 207
MX - Messico 171
AR - Argentina 124
PL - Polonia 121
ZA - Sudafrica 89
BE - Belgio 79
ID - Indonesia 79
IQ - Iraq 79
CO - Colombia 70
NL - Olanda 63
PK - Pakistan 63
ES - Italia 58
EC - Ecuador 55
UZ - Uzbekistan 47
PH - Filippine 44
VE - Venezuela 38
SA - Arabia Saudita 35
LT - Lituania 34
MA - Marocco 32
CL - Cile 31
TN - Tunisia 30
MY - Malesia 27
AE - Emirati Arabi Uniti 24
AT - Austria 24
PY - Paraguay 22
IR - Iran 21
KR - Corea 21
EG - Egitto 20
KE - Kenya 20
PE - Perù 20
UY - Uruguay 18
CZ - Repubblica Ceca 17
IL - Israele 17
JM - Giamaica 17
JO - Giordania 17
RO - Romania 15
AU - Australia 14
DZ - Algeria 13
AL - Albania 11
CH - Svizzera 11
NP - Nepal 11
BO - Bolivia 10
CR - Costa Rica 9
ET - Etiopia 9
HN - Honduras 9
LB - Libano 9
TT - Trinidad e Tobago 9
BH - Bahrain 8
AZ - Azerbaigian 7
IE - Irlanda 7
PA - Panama 7
TH - Thailandia 7
GR - Grecia 6
GT - Guatemala 6
NZ - Nuova Zelanda 6
SN - Senegal 6
BG - Bulgaria 5
DO - Repubblica Dominicana 5
EU - Europa 5
HR - Croazia 5
KZ - Kazakistan 5
OM - Oman 5
PT - Portogallo 5
QA - Qatar 5
SV - El Salvador 5
DK - Danimarca 4
HU - Ungheria 4
KG - Kirghizistan 4
NI - Nicaragua 4
NO - Norvegia 4
PR - Porto Rico 4
PS - Palestinian Territory 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BJ - Benin 3
CI - Costa d'Avorio 3
LV - Lettonia 3
MM - Myanmar 3
MT - Malta 3
NG - Nigeria 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
Totale 46.352
Città #
Ashburn 2.885
Singapore 2.720
Fairfield 2.364
Woodbridge 2.350
Houston 1.600
Jacksonville 1.434
San Jose 1.363
Ann Arbor 1.248
Chandler 1.102
Hong Kong 1.028
Santa Clara 1.005
Beijing 1.001
Seattle 929
Wilmington 848
Cambridge 789
Dallas 556
Los Angeles 453
Izmir 441
Nanjing 415
New York 390
Ho Chi Minh City 372
Munich 310
Council Bluffs 283
Princeton 277
Hanoi 258
San Diego 237
Lauterbourg 229
Tokyo 222
Milan 205
Boardman 196
Dearborn 196
Helsinki 169
Ferrara 155
São Paulo 129
Nanchang 122
Brooklyn 119
Falkenstein 117
Shenyang 116
Hefei 110
Orem 110
Warsaw 109
Shanghai 105
Mexico City 104
Denver 102
London 98
Montreal 91
Addison 89
San Francisco 89
Atlanta 87
Toronto 87
Chicago 84
Falls Church 81
Phoenix 78
Turku 78
San Mateo 76
Brussels 74
Hebei 72
Tianjin 72
Auburn Hills 65
Bremen 63
Jiaxing 63
Jinan 63
Changsha 62
Buffalo 61
Boston 59
Haiphong 57
Frankfurt am Main 55
Da Nang 51
Mountain View 49
The Dalles 48
Kunming 47
Moscow 47
Stockholm 47
Johannesburg 45
Washington 44
Philadelphia 43
Chennai 42
Redwood City 41
Tashkent 41
Manchester 39
Rio de Janeiro 39
Zhengzhou 39
Poplar 38
Guangzhou 36
Norwalk 36
Ningbo 35
Belo Horizonte 34
Bologna 31
Baghdad 29
Hải Dương 29
Columbus 28
Dhaka 26
Biên Hòa 25
Medellín 25
Jakarta 24
Mumbai 24
Tappahannock 24
Curitiba 23
Des Moines 23
Charlotte 22
Totale 32.151
Nome #
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor 1.250
Dermorphin inhibits spinal nociceptive flexion reflex in humans 410
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 398
Design, synthesis and biological characterization of novel mitochondria targeted dichloroacetate-loaded compounds with antileukemic activity 343
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 341
Stimulatory effect of dermorphin, a new synthetic potent opiate-like peptide, on human growth hormone secretion 305
A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism 301
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 293
A cyclic peptide T analogue with high chemotactic activity 293
Prolactin-Releasing Activity of Dermorphin, a New Synthetic Potent Opiate-Like Peptide, in Normal Human Subjects 292
The effects of dermorphin on the endocrine system in man 284
A new selective antagonist of the nociceptin receptor 280
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 279
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 274
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 269
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 267
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 261
A new ligand for the urotensin II receptor 259
Cholinergic mediation in dermorphin-induced growth hormone secretion in man 259
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 255
2-Bromoamides as Synthons for Pseudopeptides Containing Aminodicarboxy Units 249
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 248
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 246
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 245
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 245
Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects 244
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 243
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 239
2-Aminoamides and Pseudopeptides Carrying an Amino Group Common to two Residues 238
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 236
Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline‐3‐carboxylic acid at position 2 235
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 235
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 232
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 232
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 229
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 228
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 228
Physicochemical stability of cabazitaxel and docetaxel solutions 227
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 226
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 224
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 224
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 222
Neuropeptide S receptor ligands: a patent review (2005-2016) 222
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 220
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 220
Pharmacological characterization of tachykinin tetrabranched derivatives 220
N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis 215
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 213
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 212
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 212
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 209
A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists 207
Pharmacological characterization of nociceptin receptor: an in vitro study 207
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 206
Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma 206
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. 204
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 204
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 204
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 203
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 202
Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic 202
Opioid agonists and antagonists. Peptides containing N-terminal allyl groups and/or a thiomethylene linkage in place of a peptide bond 201
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 201
Crystal structures of dipeptides containing the Dmt-Tic pharmacophore 201
Dermorphin decreases plasma LH levels in human: Evidence for a modulatory role of gonadal steroids 201
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 201
Critical role for prokineticin 2 in CNS autoimmunity 200
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 199
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 198
Structure-activity study at positions 3 and 4 of human neuropeptide S. 196
ANALOGHI DERMASEPTINICI AD ATTIVITA’ ANTIMICROBICA 196
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 194
Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: New evidence from rats and mice 188
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 188
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 188
Responses of plasma renin activity, aldosterone, adrenocorticotropin, and cortisol to dermorphin, a new synthetic potent opiate-like peptide, in man 188
Design of d-opioid peptide antagonists for emerging drug applications 187
Hydrogen sulfide induced disruption of Na+ homeostasis in the cortex 186
Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining neuropathic pain in the chronic constriction injury model 184
Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opiold receptor agonist 184
Synthetic Approach to non-Isosteric Peptidomimetics Related to Human Endothelin 183
Structure–activity relationships of cyclic and linear peptide T analogues 183
Assessment of substitution in the second pharmacophore of Dmt-Tic analogues 183
Synthesis and opioid activity of partial retro‐inverso analogs of dermorphin 182
Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A 181
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 181
Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands 180
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 179
6-N,N-dimethylamino-2,3-naphthalimide: A new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides 179
Nociceptin/orphanin FQ receptor ligands 179
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 178
Structure-activity studies on neuropeptide S - Identification of the amino acid residues crucial for receptor activation 177
Structure-activity relationship study on human urotensin II 177
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores 176
Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders. 176
Somatostatin Inhibits the Dermorphin-Stimulated Thyrotropin Release in Man 176
Synthesis and biological activity of carboxyl terminally extended dermorphins 175
Characterization of N,N(Me)(2)-Dmt-Tic-OH, a delta selective opioid dipeptide antagonist 174
The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation 174
SUPRAMOLECULAR AGGREGATES COMPRISING MALEIMIDO CORES 174
Totale 23.324
Categoria #
all - tutte 204.813
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.538
Totale 208.351


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.868 0 290 230 211 230 135 136 170 114 228 224 900
2022/20232.733 297 96 90 335 463 380 148 272 388 16 143 105
2023/20241.291 150 183 94 32 103 233 51 82 17 22 32 292
2024/20255.005 141 106 410 141 637 458 156 346 682 512 749 667
2025/202614.884 1.509 666 1.429 2.046 2.032 995 1.674 739 1.380 1.686 505 223
2026/20272.484 1.855 629 0 0 0 0 0 0 0 0 0 0
Totale 46.670